Published by Global Banking and Finance Review
Posted on September 30, 2025
1 min readLast updated: January 21, 2026
Published by Global Banking and Finance Review
Posted on September 30, 2025
1 min readLast updated: January 21, 2026
Sanofi is being investigated by the European Commission for potential antitrust violations in the vaccine sector, focusing on exclusionary practices.
BRUSSELS (Reuters) -French pharmaceutical group Sanofi said on Tuesday that representatives of the European Commission had visited its premises in France and Germany on Monday in connection with an investigation into its conduct in the seasonal flu vaccine space.
The company said it is confident that it is compliant with the relevant rules and regulations and will cooperate fully with the European Commission.
The EU executive arm said earlier on Tuesday it was carrying out unannounced inspections at the premises of a company active in the vaccines sector, without naming the firm.
The EU executive arm said it had concerns the company had violated its antitrust rules that prohibit abuses of a dominant market position. It is investigating possible exclusionary practices that may amount to anticompetitive disparagement, the commission said.
Relevant national competition authorities accompanied European Commission officials.
(Reporting by Makini Brice and GV De Clercq; Editing by Benoit Van Overstraeten)
The European Commission is investigating Sanofi due to concerns that the company may have violated antitrust rules by engaging in exclusionary practices.
The European Commission conducted unannounced inspections at Sanofi's premises in France and Germany as part of the investigation.
Sanofi stated that it is confident in its compliance with relevant rules and regulations and will fully cooperate with the European Commission during the investigation.
Explore more articles in the Headlines category